Skip to main content
Top
Published in: Journal of Translational Medicine 1/2012

Open Access 01-12-2012 | Research

Secreted protein acidic and rich in cysteine (SPARC) is associated with nasopharyngeal carcinoma metastasis and poor prognosis

Authors: Hai-Yun Wang, Yang-Yang Li, Qiong Shao, Jing-Hui Hou, Fang Wang, Man-Bo Cai, Yi-Xin Zeng, Jian-Yong Shao

Published in: Journal of Translational Medicine | Issue 1/2012

Login to get access

Abstract

Background

The aim of the present study was to analyse the expression of Secreted protein acidic and rich in cysteine (SPARC) in nasopharyngeal carcinoma (NPC) specimens, and to evaluate its correlation with clinicopathologic features, including survival of patients with NPC

Methods

NPC tissue microarrays (TMAs) were constructed from Sun Yat-sen University Cancer Center (SYSUCC), another three centers on mainland China, Singapore and Hong Kong. Using quantitative RT-PCR and Western-blotting techniques, we detected mRNA and protein expression of SPARC in NPC cell lines and immortalized nasopharyngeal epithelial cells (NPECs) induced by Bmi-1 (NPEC2 Bmi-1). The difference of SPARC expression in the cell lines was tested using a t-test method. The relationship between the SPARC expression and clinicopathological data was assessed by chi-square. Survival analysis was estimated using the Kaplan-Meier approach with log-rank test. Univariate and multivariate analyses of clinical variables were performed using Cox proportional hazards regression models.

Results

The expression levels of SPARC mRNA and protein were markedly higher in NPC cell lines than in NPEC2 Bmi-1. Especially, the expression levels of SPARC mRNA and protein were much lower in the 6-10B than in the 5-8 F (P = 0.002, P = 0.001). SPARC immunostaining revealed cytoplasmic localization in NPC cells and no staining in the stroma and epithelium.
In addition, high level of SPARC positively correlated with the status of distant metastasis (P = 0.001) and WHO histological classification (P = 0.023). NPC patients with high SPARC expression also had a significantly poorer prognosis than patients with low SPARC expression (log-rank test, P < 0.001), especially patients with advanced stage disease (log-rank, P < 0.001). Multivariate analysis suggested that the level of SPARC expression was an independent prognostic indicator for the overall survival of patients with NPC (P < 0.001).

Conclusions

SPARC expression is common in NPC patients. Our data shows that elevated SPARC expression is a potential unfavorable prognostic factor for patients with NPC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hsu MM, Tu SM: Nasopharyngeal carcinoma in Taiwan. Clinical manifestations and results of therapy. Cancer. 1983, 52: 362-368. 10.1002/1097-0142(19830715)52:2<362::AID-CNCR2820520230>3.0.CO;2-V.CrossRefPubMed Hsu MM, Tu SM: Nasopharyngeal carcinoma in Taiwan. Clinical manifestations and results of therapy. Cancer. 1983, 52: 362-368. 10.1002/1097-0142(19830715)52:2<362::AID-CNCR2820520230>3.0.CO;2-V.CrossRefPubMed
2.
go back to reference Vokes EE, Liebowitz DN, Weichselbaum RR: Nasopharyngeal carcinoma. Lancet. 1997, 350: 1087-1091. 10.1016/S0140-6736(97)07269-3.CrossRefPubMed Vokes EE, Liebowitz DN, Weichselbaum RR: Nasopharyngeal carcinoma. Lancet. 1997, 350: 1087-1091. 10.1016/S0140-6736(97)07269-3.CrossRefPubMed
3.
go back to reference Cvitkovic E, Bachouchi M, Boussen H, Busson P, Rousselet G, Mahjoubi R, Flores P, Tursz T, Armand JP, Azli N: Leukemoid reaction, bone marrow invasion, fever of unknown origin, and metastatic pattern in the natural history of advanced undifferentiated carcinoma of nasopharyngeal type: a review of 255 consecutive cases. J Clin Oncol. 1993, 11: 2434-2442.PubMed Cvitkovic E, Bachouchi M, Boussen H, Busson P, Rousselet G, Mahjoubi R, Flores P, Tursz T, Armand JP, Azli N: Leukemoid reaction, bone marrow invasion, fever of unknown origin, and metastatic pattern in the natural history of advanced undifferentiated carcinoma of nasopharyngeal type: a review of 255 consecutive cases. J Clin Oncol. 1993, 11: 2434-2442.PubMed
4.
go back to reference Ahmad A, Stefani S: Distant metastases of nasopharyngeal carcinoma: a study of 256 male patients. J Surg Oncol. 1986, 33: 194-197. 10.1002/jso.2930330310.CrossRefPubMed Ahmad A, Stefani S: Distant metastases of nasopharyngeal carcinoma: a study of 256 male patients. J Surg Oncol. 1986, 33: 194-197. 10.1002/jso.2930330310.CrossRefPubMed
5.
go back to reference Chan AS, To KF, Lo KW, Mak KF, Pak W, Chiu B, Tse GM, Ding M, Li X, Lee JC, Huang DP: High frequency of chromosome 3p deletion in histologically normal nasopharyngeal epithelia from southern Chinese. Cancer Res. 2000, 60: 5365-5370.PubMed Chan AS, To KF, Lo KW, Mak KF, Pak W, Chiu B, Tse GM, Ding M, Li X, Lee JC, Huang DP: High frequency of chromosome 3p deletion in histologically normal nasopharyngeal epithelia from southern Chinese. Cancer Res. 2000, 60: 5365-5370.PubMed
6.
go back to reference Hong MH, Mai HQ, Min HQ, Ma J, Zhang EP, Cui NJ: A comparison of the Chinese 1992 and fifth-edition International Union Against Cancer staging systems for staging nasopharyngeal carcinoma. Cancer. 2000, 89: 242-247. 10.1002/1097-0142(20000715)89:2<242::AID-CNCR6>3.0.CO;2-Z.CrossRefPubMed Hong MH, Mai HQ, Min HQ, Ma J, Zhang EP, Cui NJ: A comparison of the Chinese 1992 and fifth-edition International Union Against Cancer staging systems for staging nasopharyngeal carcinoma. Cancer. 2000, 89: 242-247. 10.1002/1097-0142(20000715)89:2<242::AID-CNCR6>3.0.CO;2-Z.CrossRefPubMed
7.
go back to reference Heng DM, Wee J, Fong KW, Lian LG, Sethi VK, Chua ET, Yang TL, Khoo-Tan HS, Lee KS, Lee KM: Prognostic factors in 677 patients in Singapore with nondisseminated nasopharyngeal carcinoma. Cancer. 1999, 86: 1912-1920. 10.1002/(SICI)1097-0142(19991115)86:10<1912::AID-CNCR6>3.0.CO;2-S.CrossRefPubMed Heng DM, Wee J, Fong KW, Lian LG, Sethi VK, Chua ET, Yang TL, Khoo-Tan HS, Lee KS, Lee KM: Prognostic factors in 677 patients in Singapore with nondisseminated nasopharyngeal carcinoma. Cancer. 1999, 86: 1912-1920. 10.1002/(SICI)1097-0142(19991115)86:10<1912::AID-CNCR6>3.0.CO;2-S.CrossRefPubMed
8.
go back to reference Baranska B, Kujawa M, Szulborski K: Formation of the nemaline structures in soleus muscle of rats subjected to long-lasting immobilization. Folia Morphol (Warsz). 1999, 58: 207-214. Baranska B, Kujawa M, Szulborski K: Formation of the nemaline structures in soleus muscle of rats subjected to long-lasting immobilization. Folia Morphol (Warsz). 1999, 58: 207-214.
9.
go back to reference Tatsumi-Tamori A, Yoshizaki T, Miwa T, Furukawa M: Clinical evaluation of staging system for nasopharyngeal carcinoma: comparison of fourth and fifth editions of UICC TNM classification. Ann Otol Rhinol Laryngol. 2000, 109: 1125-1129.CrossRefPubMed Tatsumi-Tamori A, Yoshizaki T, Miwa T, Furukawa M: Clinical evaluation of staging system for nasopharyngeal carcinoma: comparison of fourth and fifth editions of UICC TNM classification. Ann Otol Rhinol Laryngol. 2000, 109: 1125-1129.CrossRefPubMed
10.
go back to reference Rhee DJ, Haddadin RI, Kang MH, Oh DJ: Matricellular proteins in the trabecular meshwork. Exp Eye Res. 2009, 88: 694-703. 10.1016/j.exer.2008.11.032.CrossRefPubMed Rhee DJ, Haddadin RI, Kang MH, Oh DJ: Matricellular proteins in the trabecular meshwork. Exp Eye Res. 2009, 88: 694-703. 10.1016/j.exer.2008.11.032.CrossRefPubMed
11.
go back to reference Maillard C, Malaval L, Delmas PD: Immunological screening of SPARC/Osteonectin in nonmineralized tissues. Bone. 1992, 13: 257-264. 10.1016/8756-3282(92)90206-C.CrossRefPubMed Maillard C, Malaval L, Delmas PD: Immunological screening of SPARC/Osteonectin in nonmineralized tissues. Bone. 1992, 13: 257-264. 10.1016/8756-3282(92)90206-C.CrossRefPubMed
12.
go back to reference Porter PL, Sage EH, Lane TF, Funk SE, Gown AM: Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem. 1995, 43: 791-800. 10.1177/43.8.7622842.CrossRefPubMed Porter PL, Sage EH, Lane TF, Funk SE, Gown AM: Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem. 1995, 43: 791-800. 10.1177/43.8.7622842.CrossRefPubMed
13.
go back to reference Wang CS, Lin KH, Chen SL, Chan YF, Hsueh S: Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance. Br J Cancer. 2004, 91: 1924-1930. 10.1038/sj.bjc.6602213.CrossRefPubMedPubMedCentral Wang CS, Lin KH, Chen SL, Chan YF, Hsueh S: Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance. Br J Cancer. 2004, 91: 1924-1930. 10.1038/sj.bjc.6602213.CrossRefPubMedPubMedCentral
14.
go back to reference Zhao ZS, Wang YY, Chu YQ, Ye ZY, Tao HQ: SPARC is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res. 2010, 16: 260-268. 10.1158/1078-0432.CCR-09-1247.CrossRefPubMed Zhao ZS, Wang YY, Chu YQ, Ye ZY, Tao HQ: SPARC is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res. 2010, 16: 260-268. 10.1158/1078-0432.CCR-09-1247.CrossRefPubMed
15.
go back to reference Bergamaschi A, Tagliabue E, Sorlie T, Naume B, Triulzi T, Orlandi R, Russnes HG, Nesland JM, Tammi R, Auvinen P: Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol. 2008, 214: 357-367. 10.1002/path.2278.CrossRefPubMed Bergamaschi A, Tagliabue E, Sorlie T, Naume B, Triulzi T, Orlandi R, Russnes HG, Nesland JM, Tammi R, Auvinen P: Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol. 2008, 214: 357-367. 10.1002/path.2278.CrossRefPubMed
16.
go back to reference Helleman J, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, Meijer-van-Gelder ME, Sieuwerts AM, Klijn JG, Sleijfer S, Foekens JA, Berns EM: Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin Cancer Res. 2008, 14: 5555-5564. 10.1158/1078-0432.CCR-08-0555.CrossRefPubMed Helleman J, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, Meijer-van-Gelder ME, Sieuwerts AM, Klijn JG, Sleijfer S, Foekens JA, Berns EM: Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin Cancer Res. 2008, 14: 5555-5564. 10.1158/1078-0432.CCR-08-0555.CrossRefPubMed
17.
go back to reference Watkins G, Douglas-Jones A, Bryce R, Mansel RE, Jiang WG: Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids. 2005, 72: 267-272. 10.1016/j.plefa.2004.12.003.CrossRefPubMed Watkins G, Douglas-Jones A, Bryce R, Mansel RE, Jiang WG: Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids. 2005, 72: 267-272. 10.1016/j.plefa.2004.12.003.CrossRefPubMed
18.
go back to reference Dalla-Torre CA, Yoshimoto M, Lee CH, Joshua AM, de Toledo SR, Petrilli AS, Andrade JA, Chilton-MacNeill S, Zielenska M, Squire JA: Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma. BMC Cancer. 2006, 6: 237-10.1186/1471-2407-6-237.CrossRefPubMedPubMedCentral Dalla-Torre CA, Yoshimoto M, Lee CH, Joshua AM, de Toledo SR, Petrilli AS, Andrade JA, Chilton-MacNeill S, Zielenska M, Squire JA: Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma. BMC Cancer. 2006, 6: 237-10.1186/1471-2407-6-237.CrossRefPubMedPubMedCentral
19.
go back to reference Rich JN, Hans C, Jones B, Iversen ES, McLendon RE, Rasheed BK, Dobra A, Dressman HK, Bigner DD, Nevins JR, West M: Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res. 2005, 65: 4051-4058. 10.1158/0008-5472.CAN-04-3936.CrossRefPubMed Rich JN, Hans C, Jones B, Iversen ES, McLendon RE, Rasheed BK, Dobra A, Dressman HK, Bigner DD, Nevins JR, West M: Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res. 2005, 65: 4051-4058. 10.1158/0008-5472.CAN-04-3936.CrossRefPubMed
20.
go back to reference Yamashita K, Upadhay S, Mimori K, Inoue H, Mori M: Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression. Cancer. 2003, 97: 2412-2419. 10.1002/cncr.11368.CrossRefPubMed Yamashita K, Upadhay S, Mimori K, Inoue H, Mori M: Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression. Cancer. 2003, 97: 2412-2419. 10.1002/cncr.11368.CrossRefPubMed
21.
go back to reference Yamanaka M, Kanda K, Li NC, Fukumori T, Oka N, Kanayama HO, Kagawa S: Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. J Urol. 2001, 166: 2495-2499. 10.1016/S0022-5347(05)65623-6.CrossRefPubMed Yamanaka M, Kanda K, Li NC, Fukumori T, Oka N, Kanayama HO, Kagawa S: Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. J Urol. 2001, 166: 2495-2499. 10.1016/S0022-5347(05)65623-6.CrossRefPubMed
22.
go back to reference Bozkurt SU, Ayan E, Bolukbasi F, Elmaci I, Pamir N, Sav A: Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas. APMIS. 2009, 117: 651-659. 10.1111/j.1600-0463.2009.02516.x.CrossRefPubMed Bozkurt SU, Ayan E, Bolukbasi F, Elmaci I, Pamir N, Sav A: Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas. APMIS. 2009, 117: 651-659. 10.1111/j.1600-0463.2009.02516.x.CrossRefPubMed
23.
go back to reference Kato Y, Nagashima Y, Baba Y, Kawano T, Furukawa M, Kubota A, Yanoma S, Imagawa-Ishiguro Y, Satake K, Taguchi T: Expression of SPARC in tongue carcinoma of stage II is associated with poor prognosis: an immunohistochemical study of 86 cases. Int J Mol Med. 2005, 16: 263-268.PubMed Kato Y, Nagashima Y, Baba Y, Kawano T, Furukawa M, Kubota A, Yanoma S, Imagawa-Ishiguro Y, Satake K, Taguchi T: Expression of SPARC in tongue carcinoma of stage II is associated with poor prognosis: an immunohistochemical study of 86 cases. Int J Mol Med. 2005, 16: 263-268.PubMed
24.
go back to reference Chin D, Boyle GM, Williams RM, Ferguson K, Pandeya N, Pedley J, Campbell CM, Theile DR, Parsons PG, Coman WB: Novel markers for poor prognosis in head and neck cancer. Int J Cancer. 2005, 113: 789-797. 10.1002/ijc.20608.CrossRefPubMed Chin D, Boyle GM, Williams RM, Ferguson K, Pandeya N, Pedley J, Campbell CM, Theile DR, Parsons PG, Coman WB: Novel markers for poor prognosis in head and neck cancer. Int J Cancer. 2005, 113: 789-797. 10.1002/ijc.20608.CrossRefPubMed
25.
go back to reference Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M: Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol. 1999, 30: 339-344. 10.1016/S0046-8177(99)90014-X.CrossRefPubMed Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M: Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol. 1999, 30: 339-344. 10.1016/S0046-8177(99)90014-X.CrossRefPubMed
26.
go back to reference Infante JR, Matsubayashi H, Sato N, Tonascia J, Klein AP, Riall TA, Yeo C, Iacobuzio-Donahue C, Goggins M: Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol. 2007, 25: 319-325. 10.1200/JCO.2006.07.8824.CrossRefPubMed Infante JR, Matsubayashi H, Sato N, Tonascia J, Klein AP, Riall TA, Yeo C, Iacobuzio-Donahue C, Goggins M: Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol. 2007, 25: 319-325. 10.1200/JCO.2006.07.8824.CrossRefPubMed
27.
go back to reference Mantoni TS, Schendel RR, Rodel F, Niedobitek G, Al-Assar O, Masamune A, Brunner TB: Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma. Cancer Biol Ther. 2008, 7: 1806-1815. 10.4161/cbt.7.11.6846.CrossRefPubMed Mantoni TS, Schendel RR, Rodel F, Niedobitek G, Al-Assar O, Masamune A, Brunner TB: Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma. Cancer Biol Ther. 2008, 7: 1806-1815. 10.4161/cbt.7.11.6846.CrossRefPubMed
28.
go back to reference Koukourakis MI, Giatromanolaki A, Brekken RA, Sivridis E, Gatter KC, Harris AL, Sage EH: Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res. 2003, 63: 5376-5380.PubMed Koukourakis MI, Giatromanolaki A, Brekken RA, Sivridis E, Gatter KC, Harris AL, Sage EH: Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res. 2003, 63: 5376-5380.PubMed
29.
go back to reference Min H, Hong M, Ma J, Zhang E, Zheng Q, Zhang J, Zhang F, Su Y, Qiu F: A new staging system for nasopharyngeal carcinoma in China. Int J Radiat Oncol Biol Phys. 1994, 30: 1037-1042.CrossRefPubMed Min H, Hong M, Ma J, Zhang E, Zheng Q, Zhang J, Zhang F, Su Y, Qiu F: A new staging system for nasopharyngeal carcinoma in China. Int J Radiat Oncol Biol Phys. 1994, 30: 1037-1042.CrossRefPubMed
30.
go back to reference Chua DT, Sham JS, Wei WI, Ho WK, Au GK: The predictive value of the 1997 American Joint Committee on Cancer stage classification in determining failure patterns in nasopharyngeal carcinoma. Cancer. 2001, 92: 2845-2855. 10.1002/1097-0142(20011201)92:11<2845::AID-CNCR10133>3.0.CO;2-7.CrossRefPubMed Chua DT, Sham JS, Wei WI, Ho WK, Au GK: The predictive value of the 1997 American Joint Committee on Cancer stage classification in determining failure patterns in nasopharyngeal carcinoma. Cancer. 2001, 92: 2845-2855. 10.1002/1097-0142(20011201)92:11<2845::AID-CNCR10133>3.0.CO;2-7.CrossRefPubMed
31.
go back to reference Wang HY, Sun BY, Zhu ZH, Chang ET, To KF, Hwang JS, Jiang H, Kam MK, Chen G, Cheah SL: Eight-signature classifier for prediction of nasopharnyngeal carcinoma survival. J Clin Oncol. 2011, 29: 4516-4525. 10.1200/JCO.2010.33.7741.CrossRefPubMed Wang HY, Sun BY, Zhu ZH, Chang ET, To KF, Hwang JS, Jiang H, Kam MK, Chen G, Cheah SL: Eight-signature classifier for prediction of nasopharnyngeal carcinoma survival. J Clin Oncol. 2011, 29: 4516-4525. 10.1200/JCO.2010.33.7741.CrossRefPubMed
32.
go back to reference Chen J, Hu CF, Hou JH, Shao Q, Yan LX, Zhu XF, Zeng YX, Shao JY: Epstein-Barr virus encoded latent membrane protein 1 regulates mTOR signaling pathway genes which predict poor prognosis of nasopharyngeal carcinoma. J Transl Med. 2010, 8: 30-10.1186/1479-5876-8-30.CrossRefPubMedPubMedCentral Chen J, Hu CF, Hou JH, Shao Q, Yan LX, Zhu XF, Zeng YX, Shao JY: Epstein-Barr virus encoded latent membrane protein 1 regulates mTOR signaling pathway genes which predict poor prognosis of nasopharyngeal carcinoma. J Transl Med. 2010, 8: 30-10.1186/1479-5876-8-30.CrossRefPubMedPubMedCentral
33.
go back to reference Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, Shao JY, Wu QL, Li MZ, Xia YF: Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res. 2006, 66: 6225-6232. 10.1158/0008-5472.CAN-06-0094.CrossRefPubMed Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, Shao JY, Wu QL, Li MZ, Xia YF: Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res. 2006, 66: 6225-6232. 10.1158/0008-5472.CAN-06-0094.CrossRefPubMed
34.
go back to reference Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, Shao JY: MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008, 14: 2348-2360. 10.1261/rna.1034808.CrossRefPubMedPubMedCentral Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, Shao JY: MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008, 14: 2348-2360. 10.1261/rna.1034808.CrossRefPubMedPubMedCentral
35.
go back to reference Sakai N, Baba M, Nagasima Y, Kato Y, Hirai K, Kondo K, Kobayashi K, Yoshida M, Kaneko S, Kishida T: SPARC expression in primary human renal cell carcinoma: upregulation of SPARC in sarcomatoid renal carcinoma. Hum Pathol. 2001, 32: 1064-1070. 10.1053/hupa.2001.28244.CrossRefPubMed Sakai N, Baba M, Nagasima Y, Kato Y, Hirai K, Kondo K, Kobayashi K, Yoshida M, Kaneko S, Kishida T: SPARC expression in primary human renal cell carcinoma: upregulation of SPARC in sarcomatoid renal carcinoma. Hum Pathol. 2001, 32: 1064-1070. 10.1053/hupa.2001.28244.CrossRefPubMed
36.
go back to reference Takano T, Hasegawa Y, Matsuzuka F, Miyauchi A, Yoshida H, Higashiyama T, Kuma K, Amino N: Gene expression profiles in thyroid carcinomas. Br J Cancer. 2000, 83: 1495-1502. 10.1054/bjoc.2000.1483.CrossRefPubMedPubMedCentral Takano T, Hasegawa Y, Matsuzuka F, Miyauchi A, Yoshida H, Higashiyama T, Kuma K, Amino N: Gene expression profiles in thyroid carcinomas. Br J Cancer. 2000, 83: 1495-1502. 10.1054/bjoc.2000.1483.CrossRefPubMedPubMedCentral
37.
go back to reference Menon PM, Gutierrez JA, Rempel SA: A study of SPARC and vitronectin localization and expression in pediatric and adult gliomas: high SPARC secretion correlates with decreased migration on vitronectin. Int J Oncol. 2000, 17: 683-693.PubMed Menon PM, Gutierrez JA, Rempel SA: A study of SPARC and vitronectin localization and expression in pediatric and adult gliomas: high SPARC secretion correlates with decreased migration on vitronectin. Int J Oncol. 2000, 17: 683-693.PubMed
38.
go back to reference Le Bail B, Faouzi S, Boussarie L, Guirouilh J, Blanc JF, Carles J, Bioulac-Sage P, Balabaud C, Rosenbaum J: Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma. J Pathol. 1999, 189: 46-52. 10.1002/(SICI)1096-9896(199909)189:1<46::AID-PATH392>3.0.CO;2-X.CrossRefPubMed Le Bail B, Faouzi S, Boussarie L, Guirouilh J, Blanc JF, Carles J, Bioulac-Sage P, Balabaud C, Rosenbaum J: Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma. J Pathol. 1999, 189: 46-52. 10.1002/(SICI)1096-9896(199909)189:1<46::AID-PATH392>3.0.CO;2-X.CrossRefPubMed
39.
go back to reference O'Sullivan B: Nasopharynx cancer: therapeutic value of chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2007, 69: S118-S121.CrossRefPubMed O'Sullivan B: Nasopharynx cancer: therapeutic value of chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2007, 69: S118-S121.CrossRefPubMed
40.
go back to reference Wei WI, Sham JS: Nasopharyngeal carcinoma. Lancet. 2005, 365: 2041-2054. 10.1016/S0140-6736(05)66698-6.CrossRefPubMed Wei WI, Sham JS: Nasopharyngeal carcinoma. Lancet. 2005, 365: 2041-2054. 10.1016/S0140-6736(05)66698-6.CrossRefPubMed
41.
go back to reference Razak AR, Siu LL, Liu FF, Ito E, O'Sullivan B, Chan K: Nasopharyngeal carcinoma: the next challenges. Eur J Cancer. 2010, 46: 1967-1978. 10.1016/j.ejca.2010.04.004.CrossRefPubMed Razak AR, Siu LL, Liu FF, Ito E, O'Sullivan B, Chan K: Nasopharyngeal carcinoma: the next challenges. Eur J Cancer. 2010, 46: 1967-1978. 10.1016/j.ejca.2010.04.004.CrossRefPubMed
42.
go back to reference Chien YC, Chen JY, Liu MY, Yang HI, Hsu MM, Chen CJ, Yang CS: Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med. 2001, 345: 1877-1882. 10.1056/NEJMoa011610.CrossRefPubMed Chien YC, Chen JY, Liu MY, Yang HI, Hsu MM, Chen CJ, Yang CS: Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med. 2001, 345: 1877-1882. 10.1056/NEJMoa011610.CrossRefPubMed
43.
go back to reference Greenwood JA, Murphy-Ullrich JE: Signaling of de-adhesion in cellular regulation and motility. Microsc Res Tech. 1998, 43: 420-432. 10.1002/(SICI)1097-0029(19981201)43:5<420::AID-JEMT8>3.0.CO;2-B.CrossRefPubMed Greenwood JA, Murphy-Ullrich JE: Signaling of de-adhesion in cellular regulation and motility. Microsc Res Tech. 1998, 43: 420-432. 10.1002/(SICI)1097-0029(19981201)43:5<420::AID-JEMT8>3.0.CO;2-B.CrossRefPubMed
44.
go back to reference Tai IT, Tang MJ: SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Updat. 2008, 11: 231-246. 10.1016/j.drup.2008.08.005.CrossRefPubMed Tai IT, Tang MJ: SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Updat. 2008, 11: 231-246. 10.1016/j.drup.2008.08.005.CrossRefPubMed
45.
go back to reference Huang DY, Lin YT, Jan PS, Hwang YC, Liang ST, Peng Y, Huang CY, Wu HC, Lin CT: Transcription factor SOX-5 enhances nasopharyngeal carcinoma progression by down-regulating SPARC gene expression. J Pathol. 2008, 214: 445-455.CrossRefPubMed Huang DY, Lin YT, Jan PS, Hwang YC, Liang ST, Peng Y, Huang CY, Wu HC, Lin CT: Transcription factor SOX-5 enhances nasopharyngeal carcinoma progression by down-regulating SPARC gene expression. J Pathol. 2008, 214: 445-455.CrossRefPubMed
46.
go back to reference Framson PE, Sage EH: SPARC and tumor growth: where the seed meets the soil?. J Cell Biochem. 2004, 92: 679-690. 10.1002/jcb.20091.CrossRefPubMed Framson PE, Sage EH: SPARC and tumor growth: where the seed meets the soil?. J Cell Biochem. 2004, 92: 679-690. 10.1002/jcb.20091.CrossRefPubMed
47.
go back to reference Podhajcer OL, Benedetti LG, Girotti MR, Prada F, Salvatierra E, Llera AS: The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev. 2008, 27: 691-705. 10.1007/s10555-008-9146-7.CrossRefPubMed Podhajcer OL, Benedetti LG, Girotti MR, Prada F, Salvatierra E, Llera AS: The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev. 2008, 27: 691-705. 10.1007/s10555-008-9146-7.CrossRefPubMed
48.
go back to reference Clark CJ, Sage EH: A prototypic matricellular protein in the tumor microenvironment-where there's SPARC, there's fire. J Cell Biochem. 2008, 104: 721-732. 10.1002/jcb.21688.CrossRefPubMed Clark CJ, Sage EH: A prototypic matricellular protein in the tumor microenvironment-where there's SPARC, there's fire. J Cell Biochem. 2008, 104: 721-732. 10.1002/jcb.21688.CrossRefPubMed
49.
go back to reference Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U: Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA. 2004, 101: 811-816. 10.1073/pnas.0304146101.CrossRefPubMedPubMedCentral Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U: Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA. 2004, 101: 811-816. 10.1073/pnas.0304146101.CrossRefPubMedPubMedCentral
50.
go back to reference Thomas R, True LD, Bassuk JA, Lange PH, Vessella RL: Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res. 2000, 6: 1140-1149.PubMed Thomas R, True LD, Bassuk JA, Lange PH, Vessella RL: Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res. 2000, 6: 1140-1149.PubMed
51.
go back to reference Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM: Delineation of prognostic biomarkers in prostate cancer. Nature. 2001, 412: 822-826. 10.1038/35090585.CrossRefPubMed Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM: Delineation of prognostic biomarkers in prostate cancer. Nature. 2001, 412: 822-826. 10.1038/35090585.CrossRefPubMed
52.
go back to reference Kunigal S, Gondi CS, Gujrati M, Lakka SS, Dinh DH, Olivero WC, Rao JS: SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA. Int J Oncol. 2006, 29: 1349-1357.PubMedPubMedCentral Kunigal S, Gondi CS, Gujrati M, Lakka SS, Dinh DH, Olivero WC, Rao JS: SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA. Int J Oncol. 2006, 29: 1349-1357.PubMedPubMedCentral
53.
go back to reference Kong QL, Guan S, Guo BH, Zeng MS: Pre-malignant nasopharyngeal epithelial cell models. Ai Zheng. 2009, 28: 1012-1015.PubMed Kong QL, Guan S, Guo BH, Zeng MS: Pre-malignant nasopharyngeal epithelial cell models. Ai Zheng. 2009, 28: 1012-1015.PubMed
54.
go back to reference Chlenski A, Liu S, Crawford SE, Volpert OV, DeVries GH, Evangelista A, Yang Q, Salwen HR, Farrer R, Bray J, Cohn SL: SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res. 2002, 62: 7357-7363.PubMed Chlenski A, Liu S, Crawford SE, Volpert OV, DeVries GH, Evangelista A, Yang Q, Salwen HR, Farrer R, Bray J, Cohn SL: SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res. 2002, 62: 7357-7363.PubMed
Metadata
Title
Secreted protein acidic and rich in cysteine (SPARC) is associated with nasopharyngeal carcinoma metastasis and poor prognosis
Authors
Hai-Yun Wang
Yang-Yang Li
Qiong Shao
Jing-Hui Hou
Fang Wang
Man-Bo Cai
Yi-Xin Zeng
Jian-Yong Shao
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2012
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-10-27

Other articles of this Issue 1/2012

Journal of Translational Medicine 1/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.